Hand-Foot-Genital Syndrome

Clinical characteristics.

Hand-foot-genital syndrome (HFGS) is characterized by limb malformations and urogenital defects. Mild-to-severe bilateral shortening of the thumbs and great toes, caused primarily by shortening of the distal phalanx and/or the first metacarpal or metatarsal, is the most common limb malformation and results in impaired dexterity or apposition of the thumbs. Urogenital malformations include abnormalities of the ureters and urethra and various degrees of incomplete müllerian fusion in females, and hypospadias of variable severity with or without chordee in males. Vesicoureteral reflux, recurrent urinary tract infections, and chronic pyelonephritis may occur; fertility is normal.

Diagnosis/testing.

Diagnosis is based on physical examination including radiographs of the hands and feet and imaging studies of the kidneys, bladder, and female reproductive tract. Identification of a heterozygous HOXA13 pathogenic variant can establish the diagnosis if clinical and radiographic features are inconclusive. Approximately 50%-60% of pathogenic variants are polyalanine expansions.

Management.

Treatment of manifestations: Hand or foot surgery is not usually necessary. Ureteric reimplantation and surgical correction of bladder outlet abnormalities are often necessary. Surgical removal of a longitudinal vaginal septum is rarely indicated. Surgery for removal of a uterine septum or reunification of a bicornuate uterus is exceptional in the absence of recurrent mid-trimester pregnancy loss. Hymenectomy may be necessary for tight constriction ring.

Prevention of secondary complications: Prophylactic antibiotics or surgery as needed to prevent urinary tract infections or other complications of ureteral reflux or ureteropelvic junction obstruction; gynecologic examination prior to menstruation for small hymenal opening; pre-pregnancy evaluation of the vaginal and uterine anatomy because of the increased risk for premature labor and fetal loss associated with structural abnormalities of the uterus.

Surveillance: Follow up with a urologist in the presence of vesicoureteral reflux and/or documented urinary tract infection.

Genetic counseling.

Hand-foot-genital syndrome is inherited in an autosomal dominant manner. The proportion of cases caused by a de novo pathogenic variant is unknown because of the small number of individuals described. If a parent of the proband is affected, the recurrence risk to the sibs is 50%. If the proband has a known HOXA13 pathogenic variant that cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is slightly greater than that of the general population because of the possibility of parental germline mosaicism. Each child of an individual with HFGS has a 50% chance of inheriting the pathogenic variant. Prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible if the pathogenic variant in the family is known.

Suggestive Findings

Hand-foot-genital syndrome should be suspected in individuals with the following clinical and radiographic features.

Establishing the Diagnosis

The diagnosis of hand-foot-genital syndrome is established in a proband with characteristic fully penetrant limb malformations described in Suggestive Findings with or without incompletely penetrant urogenital defects.

The diagnosis of hand-foot-genital syndrome can be confirmed in a proband who has one of the following on molecular genetic testing (see Table 1):

• A heterozygous polyalanine expansion involving HOXA13 (~50%-60% of affected individuals) [Quinonez & Innis 2014]
• A heterozygous sequence variant involving HOXA13 (35% of affected individuals) [Quinonez & Innis 2014]

Allele sizes. HOXA13 protein has three extended polyalanine tracts encoded in the first exon, referred to as Tracts I, II, and III. Approximately 50%-60% of individuals with HFGS have a polyalanine expansion of one of the tracts. No affected individual has been described with expansions in more than one tract.

• Normal alleles
  • Tract I. p.Ala38[14] residues
  • Tract II. p.Ala73[12] residues
  • Tract III. p.Ala116[8], p.Ala116[12], or p.Ala116[18] residues
• Reduced-penetrance alleles. Not reported
• Full-penetrance alleles
  • Tract I. An allele with eight additional alanine residues (termed "+8" alleles) was reported in association with HFGS [Innis et al 2004].
  • Tract II. An allele with six additional alanine residues (termed "+6" alleles) was reported in association with HFGS [Frisén et al 2003].
  • Tract III. Polyalanine expansions of at least six additional polyalanine residues (termed "+6" alleles) to as many as 14 additional polyalanine residues (termed "+14" alleles) [Innis et al 2004, Utsch et al 2007] may cause HFGS.
• Alleles of questionable significance – Tract III
  • The significance of a shortened allele of eight polyalanine residues observed in one family is not clear given the occurrence of another disorder in the same family that complicates interpretation of the skeletal phenotype [Innis et al 2004]. A shortened allele of eight polyalanine residues was also reported in an unaffected woman [Owens et al 2013].
  • It is unknown whether a shortened allele of 12 polyalanine residues observed in expressed sequence tag databases [Lavoie et al 2003] is associated with phenotypic variation.

Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing, multigene panel) and comprehensive genomic testing (exome sequencing, genome sequencing) depending on the phenotype.

Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Because the phenotype of hand-foot-genital syndrome is broad, individuals with the distinctive findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those with a phenotype indistinguishable from many other inherited disorders with limb anomalies and/or urogenital anomalies are more likely to be diagnosed using genomic testing (see Option 2).

Option 2

When the phenotype is indistinguishable from many other inherited disorders characterized by limb anomalies, comprehensive genomic testing (which does not require the clinician to determine which gene[s] are likely involved) can be considered. To date, next-generation sequencing strategies cannot identify expanded repeats and therefore cannot confirm the diagnosis in the majority of individuals with HFGS. Exome sequencing is most commonly used; genome sequencing is also possible.

For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

Table 1.

Molecular Genetic Testing Used in Hand-Foot-Genital Syndrome

Clinical Description

Hand-foot-genital syndrome (HFGS) has been reported in several families and individuals [Mortlock & Innis 1997, Devriendt et al 1999, Goodman et al 2000, Debeer et al 2002, Innis et al 2002, Utsch et al 2002, Frisén et al 2003, Innis et al 2004, Owens et al 2013]. Although some minor variation in the severity of limb defects may be observed, the defects are usually similar bilaterally. The radius/ulna, humerus, tibia/fibula, and femur are normal. With the exception of thenar hypoplasia, abnormalities of muscle have not been reported. There is intrafamilial variability.

HFGS may first be suspected in infants or children during evaluation for urogenital problems including hypospadias, ureteral reflux, urethral misplacement, recurrent urinary tract infections, or chronic pyelonephritis, or for small thumbs with impaired dexterity or apposition. Renal insufficiency leading to renal transplantation has been reported in one female.

Of all affected males, only one has had a documented history of urinary tract infection (UTI); two brothers had hypospadias (Grades II and III); one had bilateral vesicoureteral reflux with UTI, and the other had ureteropelvic junction (UPJ) obstruction. This family was first reported by Verp et al [1983] (family 1) and later by Donnenfeld et al [1992]. Retrograde ejaculation was reported in one affected male [Debeer et al 2002].

Affected males are not at increased risk for cryptorchidism and are fertile. No anomalies of the prostate or seminal vesicles have been described; however, directed examinations in males with HFGS to evaluate for such abnormalities have not been reported.

Menarche is usually normal. Females with varying degrees of incomplete müllerian fusion are at increased risk for premature labor, premature birth, second-trimester fetal loss, or stillbirth.

Other, possibly unrelated abnormalities are found rarely in individuals or families with HFGS:

• Strabismus
• Ventriculoseptal defect (propositus of Stern et al [1970])
• Inguinal hernia, epididymal cyst, short stature, cervical ribs, supernumerary nipple, lower limit of functioning, onychodysplasia
• Sacral dimple
• Psychomotor retardation, microcephaly, and hypertelorism (in 1 of 4 affected members of a single family in which HFGS occurs)
• Difficulty with balance when standing (in 1 adult)

The following are normal:

• Developmental milestones
• External ears and hearing

Genotype-Phenotype Correlations

Although the number of affected individuals in whom pathogenic variants in HOXA13 have been identified is small, some genotype-phenotype correlations are emerging.

The limb malformations in individuals with the heterozygous pathogenic nonsense variants in either exon 1 or 2 or a polyalanine expansion in exon 1 are similar to those described in individuals with a cytogenetic deletion of the HOXA cluster and adjacent genomic DNA [Devriendt et al 1999, Tas et al 2017], suggesting that these typical features result from HOXA13 haploinsufficiency. Minor differences may be attributable to effects of other genetic loci or stochastic variables.

Generally speaking, HOXA13 homeodomain pathogenic missense variants appear to produce more severe features or unusual digital malformations; the variant p.Asn372His was associated with a severe skeletal phenotype [Goodman et al 2000].

The variables that determine whether an individual heterozygous for a HOXA13 pathogenic variant develops genitourinary problems are not clear. Hypospadias does not always occur in males with HOXA13 pathogenic variants. When it does, it is most often glandular, although variability in severity occurs even in males with the same pathogenic variant. Females may be likely to have more severe genitourinary tract problems than males [Innis et al 2004]. The small number of families described limits further conclusions, although females with polyalanine expansions may have a greater frequency of urinary tract problems [Innis et al 2004].

Penetrance

Skeletal defects are 100% penetrant.

Penetrance for urogenital malformations is greater than 50% overall and may be greater for affected females.

Anticipation

Anticipation is not observed. Polyalanine expansions are stable for many generations.

Prevalence

HFGS is extremely rare.

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with hand-foot-genital syndrome (HFGS), the evaluations summarized in Table 3 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

Table 3.

Recommended Evaluations Following Initial Diagnosis in Individuals with Hand-Foot-Genital Syndrome

Treatment of Manifestations

Table 4.

Treatment of Manifestations in Individuals with Hand-Foot-Genital Syndrome

Prevention of Secondary Complications

The following are appropriate:

• Prophylactic antibiotics or surgery as needed to prevent urinary tract infections or other complications of ureteral reflux or UPJ obstruction
• Gynecologic examination prior to menstruation for small hymenal opening
• Pre-pregnancy evaluation of the vaginal and uterine anatomy because of the increased risk for premature labor and fetal loss associated with structural abnormalities of the uterus

Surveillance

Follow up with a urologist in the presence of vesicoureteral reflux and/or documented urinary tract infection is warranted.

Evaluation of Relatives at Risk

It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an affected individual in order to identify those at risk for genitourinary and reproductive tract complications.

Evaluations can include:

• Molecular genetic testing if the HOXA13 pathogenic variant in the family is known;
• Physical examination, radiographic examination of hands and feet, and consideration of referral for urologic and/or gynecologic examination if the pathogenic variant in the family is not known.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

In women with HFGS, pregnancy loss is possible secondary to uterine malformation. Consultation with an obstetrician before pregnancy is recommended and should include evaluation for and discussion of potential pregnancy complications. Affected fetuses are generally healthy, but could be at risk for premature birth secondary to maternal uterine malformation if the mother is also affected.

Therapies Under Investigation

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Mode of Inheritance

Hand-foot-genital syndrome (HFGS) is inherited in an autosomal dominant manner.

Risk to Family Members

Parents of a proband

• Some individuals diagnosed with HFGS have an affected parent.
• A proband with HFGS may have the disorder as the result of a de novo HOXA13 pathogenic variant. The proportion of cases caused by de novo variants is unknown because of the small number of individuals described.
• Molecular genetic testing is recommended for the parents of a proband with an apparent de novo pathogenic variant. If a HOXA13 pathogenic variant has not been identified in the proband, recommendations may also include history and physical examination followed by radiographic examination of hands and feet, and possibly referral for urologic and/or gynecologic examination.
• If the proband has a pathogenic variant that cannot be detected in the leukocyte DNA of either parent, possible explanations include a de novo pathogenic variant in the proband or germline mosaicism in a parent. Somatic and germline mosaicism for a polyalanine expansion was reported in an unaffected parent who transmitted the polyalanine expansion to his affected offspring [Owens et al 2013].
• The family history of some individuals diagnosed with HFGS may appear to be negative because of failure to recognize the disorder in family members because of a milder phenotypic presentation or death of the parent before appropriate evaluation. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.
• Note: If the parent is the individual in whom the pathogenic variant first occurred, the parent may have somatic mosaicism for the pathogenic variant and may be mildly/minimally affected or unaffected [Owens et al 2013].

Sibs of a proband. The risk to the sibs of the proband depends on the clinical/genetic status of the proband's parents:

• If a parent of the proband is affected and/or is known to have the HOXA13 pathogenic variant identified in the proband, the risk to the sibs is 50%.
• If the proband has a known HOXA13 pathogenic variant that cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is slightly greater than that of the general population because of the possibility of parental germline mosaicism [Owens et al 2013].

Offspring of a proband. Each child of an individual with HFGS has a 50% chance of inheriting the HOXA13 pathogenic variant.

Other family members. The risk to other family members depends on the genetic status of the proband's parents: if a parent has the HOXA13 pathogenic variant, the parent's family members may be at risk.

Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

Considerations in families with an apparent de novo pathogenic variant. When neither parent of a proband with an autosomal dominant condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely de novo. However, non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.

Family planning

• The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.

DNA banking. Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown).

Prenatal Testing and Preimplantation Genetic Testing

Once the HOXA13 pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

Molecular Pathogenesis

Introduction. Quinonez & Innis [2014] and Innis [2016] reviewed historical and evolutionary information about HOX genes, their roles as highly conserved, DNA-binding transcription factors in morphogenetic processes, and the consequences of pathogenic variants in ten of the 39 human HOX genes. There are many other well-written reviews detailing the basic science mechanisms underlying HOX gene regulation and the ways in which HOX proteins exert their effects in patterning and growth, much of which has been learned through animal models.

There are four HOX gene clusters, which map to four different human chromosomes. These clusters, labeled HOXA, HOXB, HOXC, and HOXD, are located on chromosomes 7p14, 17q21, 12q13, and 2q31, respectively. Each cluster has between nine and 11 genes, and members in similar positions among clusters, called paralogs, have an identical or nearly identical 60-amino acid "homeodomain" DNA-binding domain. HOX genes are expressed along the body axis in restricted anterior-posterior domains that map relative to their position in the cluster. For example, HOXA1 is expressed more anteriorly, and HOXA13 is expressed in distal/posterior structures including the hands/feet and distal axial structures of the reproductive and gastrointestinal systems. Their expression domains coincide with areas of malformation in the presence of pathogenic variants. Pathogenic variants lead to alteration in HOX-regulated genes and changes in structural identity or size. Molecular pathogenesis is detailed in Innis [2016].

Mechanism of disease causation. For both nonsense variants and pathogenic polyalanine tract expansions of HOXA13, haploinsufficiency is likely to be the basis for malformations. This is supported by chromosome deletions involving the entire HOXA gene cluster associated with HFGS features and mouse models. However, missense variants in the homeodomain may involve altered DNA site specificity and may result in a more severe or slightly unusual phenotype as in Guttmacher syndrome [Innis et al 2002] or as described for another homeodomain variant [Wallis et al 2016]. See Genetically Related Disorders.

HOXA13-specific laboratory considerations. HFGS caused by expansion of HOXA13 polyalanine repeat tracts, which are highly GC-rich, will not be routinely detected by next-generation sequencing analysis: assays specifically designed to detect a repeat expansion are required [Mortlock et al 2000, Innis et al 2004, Owens et al 2013].

Literature Cited

• Debeer P, Bacchelli C, Scambler PJ, De Smet L, Fryns JP, Goodman FR. Severe digital abnormalities in a patient heterozygous for both a novel missense mutation in HOXD13 and a polyalanine tract expansion in HOXA13. J Med Genet. 2002;39:852–6. [PMC free article: PMC1735011] [PubMed: 12414828]

• Devriendt K, Jaeken J, Matthijs G, Van Esch H, Debeer P, Gewillig M, Fryns JP. Haploinsufficiency of the HOXA gene cluster, in a patient with hand-foot-genital syndrome, velopharyngeal insufficiency, and persistent patent ductus Botalli. Am J Hum Genet. 1999;65:249–51. [PMC free article: PMC1378097] [PubMed: 10364539]

• Donnenfeld AE, Schrager DS, Corson SL. Update on a family with hand-foot-genital syndrome: hypospadias and urinary tract abnormalities in two boys from the fourth generation. Am J Med Genet. 1992;44:482–4. [PubMed: 1442892]

• Dunø M, Hove H, Kirchhoff M, Devriendt K, Schwartz M. Mapping genomic deletions down to the base: a quantitative copy number scanning approach used to characterize and clone the breakpoints of a recurrent 7p14.2p15.l3 deletion. Hum Genet. 2004;115:459–67. [PubMed: 15378350]

• Frisén L, Lagerstedt K, Tapper-Persson M, Kockum I, Nordenskjöld A. A novel duplication in the HOXA13 gene in a family with atypical hand-foot-genital syndrome. J Med Genet. 2003;40:e49. [PMC free article: PMC1735421] [PubMed: 12676922]

• Goodman FR, Bacchelli C, Brady AF, Brueton LA, Fryns JP, Mortlock DP, Innis JW, Holmes LB, Donnenfeld AE, Feingold M, Beemer FA, Hennekam RC, Scambler PJ. Novel HOXA13 mutations and the phenotypic spectrum of hand-foot-genital syndrome. Am J Hum Genet. 2000;67:197–202. [PMC free article: PMC1287077] [PubMed: 10839976]

• Guttmacher AE. Autosomal dominant preaxial deficiency, postaxial polydactyly, and hypospadias. Am J Med Genet. 1993;46:219–22. [PubMed: 8484413]

• Halal F. A new syndrome of severe upper limb hypoplasia and Mullerian duct anomalies. Am J Med Genet. 1986;24:119–26. [PubMed: 3706400]

• Imagawa E, Kayserili H, Nishimura G, Nakashima M, Tsurusaki Y, Saitsu H, Ikegawa S, Matsumoto N, Miyake N. Severe manifestations of hand-foot-genital syndrome associated with a novel HOXA13 mutation. Am J Med Genet. 2014;164A:2398–402. [PubMed: 24934387]

• Innis JW. HOXA13: hand-foot-genital and Guttmacher syndromes. In: Epstein C, Wynshaw-Boris T, Erickson R, eds. Inborn Errors of Development. 3 ed. San Francisco: Oxford University Press; 2016.

• Innis JW, Goodman FR, Bacchelli C, Williams TM, Mortlock DP, Sateesh P, Scambler PJ, McKinnon W, Guttmacher AE. A HOXA13 allele with a missense mutation in the homeobox and a dinucleotide deletion in the promoter underlies Guttmacher syndrome. Hum Mutat. 2002;19:573–4. [PubMed: 11968094]

• Innis JW, Mortlock D, Chen Z, Ludwig M, Williams ME, Williams TM, Doyle CD, Shao Z, Glynn M, Mikulic D, Lehmann K, Mundlos S, Utsch B. Polyalanine expansion in HOXA13: three new affected families and the molecular consequences in a mouse model. Hum Mol Genet. 2004;13:2841–51. [PubMed: 15385446]

• Jorgensen EM, Ruman JI, Doherty L, Taylor HS. A novel mutation of HOXA13 in a family with hand-foot-genital syndrome and the role of polyalanine expansions in the spectrum of Müllerian fusion anomalies. Fertil Steril. 2010;94:1235–8. [PMC free article: PMC2889242] [PubMed: 19591980]

• Jun KR, Seo EJ, Lee JO, Yoo HW, Park IS, Yoon HK. Molecular cytogenetic and clinical characterization of a patient with a 5.6-Mb deletion in 7p15 including HOXA cluster. Am J Med Genet A. 2011;155A:642–7. [PubMed: 21344639]

• Lavoie H, Debeane F, Trinh QD, Turcotte JF, Corbeil-Girard LP, Dicaire MJ, Saint-Denis A, Page M, Rouleau GA, Brais B. Polymorphism, shared functions and convergent evolution of genes with sequences coding for polyalanine domains. Hum Mol Genet. 2003;12:2967–79. [PubMed: 14519685]

• Mortlock DP, Innis JW. Mutation of HOXA13 in hand-foot-genital syndrome. Nat Genet. 1997;15:179–80. [PubMed: 9020844]

• Mortlock DP, Sateesh P, Innis JW. Evolution of N-terminal sequences of the vertebrate HOXA13 protein. Mamm Genome. 2000;11:151–8. [PubMed: 10656931]

• Owens KM, Quinonez SC, Thomas PE, Keegan CE, Lefebvre N, Roulston D, Larsen CA, Stadler HS, Innis JW. Analysis of de novo HOXA13 polyalanine expansions supports replication slippage without repair in their generation. Am J Med Genet. 2013;161A:1019–27. [PubMed: 23532960]

• Pezzani L, Milani D, Manzoni F, Baccarin M, Silipiqni R, Guerneri S, Esposito S. HOXA genes cluster: clinical implications of the smallest deletion. Ital J Pediatr. 2015;41:31. [PMC free article: PMC4395968] [PubMed: 25881986]

• Quinonez SC, Innis JW. Human HOX gene disorders. Mol Genet Metab. 2014;111:4–15. [PubMed: 24239177]

• Stern AM, Gall JC Jr, Perry BL, Stimson CW, Weitkamp LR, Poznanski AK. The hand-foot-uterus syndrome: a new hereditary disorder characterized by hand and foot dysplasia, dermatoglyphic abnormalities, and partial duplication of the female genital tract. J Pediatr. 1970;77:109–16. [PubMed: 5450271]

• Tas E, Sebastian J, Madan-Khetarpal S, Sweet P, Yatsenko AN, Pollock N, Rajkovic A, Schneck FX, Yatsenko SA, Witchel SF. Familial deletion of the HOXA gene cluster associated with hand-foot-genital syndrome and phenotypic variability. Am J Med Genet. 2017;173:221–4. [PubMed: 27649277]

• Utsch B, Becker K, Brock D, Lentze MJ, Bidlingmaier F, Ludwig M. A novel stable polyalanine [poly(A)] expansion in the HOXA13 gene associated with hand-foot-genital syndrome: proper function of poly(A)-harbouring transcription factors depends on a critical repeat length? Hum Genet. 2002;110:488–94. [PubMed: 12073020]

• Utsch B, Kaya A, Ozburun A, Lentze MJ, Albers N, Ludwig M. Exclusion of WTAP and HOXA13 as candidate genes for isolated hypospadias. Scand J Urol Nephrol. 2003;37:498–501. [PubMed: 14675924]

• Utsch B, McCabe CD, Galbraith K, Gonzalez R, Born M, Dötsch J, Ludwig M, Heiko Reutter H, Innis JW. Molecular characterization of HOXA13 polyalanine expansion proteins in hand-foot-genital syndrome. Am J Med Genet. 2007;143A:3161–8. [PubMed: 17935235]

• Verp MS, Simpson JL, Elias S, Carson SA, Sarto GE, Feingold M. Heritable aspects of uterine anomalies. I. Three familial aggregates with Mullerian fusion anomalies. Fertil Steril. 1983;40:80–5. [PubMed: 6862042]

• Wallis M, Tsurusaki Y, Burgess T, Borzi P, Matsumoto N, Miyake N, True D, Patel C. Dual genetic diagnoses: atypical hand-foot-genital syndrome and developmental delay due to de novo mutations in HOXA13 and NRXN1. Am J Med Genet. 2016;170:717–24. [PubMed: 26590955]

Author Notes

Author's website

Revision History

• 8 August 2019 (sw) Comprehensive update posted live
• 3 May 2012 (me) Comprehensive update posted live
• 2 February 2010 (me) Comprehensive update posted live
• 11 July 2006 (me) Review posted live
• 16 February (jwi) Original submission